What is the current stock price of TransThera Sciences (2617.HK)?

As of December 5, 2025, TransThera Sciences (2617.HK) is trading at HK$192.0 on the Hong Kong Stock Exchange (HKSE). The stock price has decreased by 0.52% from its previous close.

Why is TransThera Sciences (2617.HK) considered a top loser?

Recently, the stock experienced a minor decrease and has lower trading volumes. Despite these short-term fluctuations, it is important to consider long-term growth metrics.

What is Tinengotinib (TT-00420)?

Tinengotinib (TT-00420) is a small molecule therapy developed by TransThera Sciences, targeting drug-resistant cancers. It has shown promising results in recent clinical trials.

How volatile is TransThera Sciences' stock?

The stock has a relatively high volatility with an Average True Range (ATR) of 16.73, indicating broader price swings in the short term. This should be considered when making investment decisions.

What are the future price targets for TransThera Sciences?

Market forecasts predict a quarterly target of HK$301.5, with long-term growth expectations reaching up to HK$1,061.59 in three years, according to Meyka AI.

HK Stocks

Analyzing TransThera Sciences (2617.HK): Market Performance and Future Prospects

ByHuzaifa Zahoor December 5, 2025December 5, 2025

TransThera Sciences (2617.HK) is making waves on the Hong Kong Stock Exchange with its innovative approaches in the biopharmaceutical sector. Despite recent fluctuations, the company has shown remarkable performance over the past year. Let’s delve deeper into its market dynamics and future prospects.